Suppr超能文献

接种疫苗挽救生命:慢性病和重症 COVID-19 感染患者的实时研究。

Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection.

机构信息

From the Indian Council of Medical Research, New Delhi, India.

Postgraduate Institute of Medical Education & Research, Chandigarh, India.

出版信息

QJM. 2023 Feb 14;116(1):47-56. doi: 10.1093/qjmed/hcac202.

Abstract

OBJECTIVES

This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalized coronavirus disease 2019 (COVID-19) adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC).

METHODS

NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October 2021 were examined.

RESULTS

Analysis of 29 509 hospitalized, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18 752 (63.6%)] showed that 15 678 (53.1%) had at least one comorbidity. Among 25 715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n = 3957). Adjusted odds of dying were significantly higher in age group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy and tuberculosis, presenting with dyspnoea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6-7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4-0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3-0.7)] were protected from in-hospital mortality.

CONCLUSIONS

WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality.

摘要

目的

本研究旨在描述住院的 2019 冠状病毒病(COVID-19)成年患者的人口统计学和临床特征,并确定纳入国家 COVID-19 临床登记处(NCRC)的住院 COVID-19 患者的结局决定因素。

方法

NCRC 是一个在印度 42 家医院运行的正在进行的数据收集平台。分析了 2020 年 9 月 1 日至 2021 年 10 月 26 日期间纳入 NCRC 的住院 COVID-19 患者的数据。

结果

对 29509 名住院成年 COVID-19 患者(平均年龄[标准差]:51.1[16.2]岁;男性:18752[63.6%])的分析显示,15678 名(53.1%)患者至少有一种合并症。在 25715 名(87.1%)有症状的患者中,发热是最常见的症状(72.3%),其次是呼吸急促(48.9%)和干咳(45.5%)。住院死亡率为 14.5%(n=3957)。年龄≥60 岁、男性、患有糖尿病、慢性肾脏病、慢性肝病、恶性肿瘤和结核病、出现呼吸困难和神经症状的患者,死亡的调整后比值比显著更高。入院时的世界卫生组织等级量表 4 或以上的患者死亡风险最高[5.6(95%置信区间:4.6-7.0)]。接受一剂[比值比:0.5(95%置信区间:0.4-0.7)]或两剂抗 SARS-CoV-2 疫苗的患者[比值比:0.4(95%置信区间:0.3-0.7)]可降低住院死亡率。

结论

入院时的世界卫生组织等级量表是 COVID-19 患者住院死亡的最重要独立预测因素。抗 SARS-CoV2 疫苗可显著降低死亡率。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验